The EEC, Eye-Movements and Dreams of the Blind

It was found that characteristic frontal EEG waves significantly often precede the rapid eye movements of dreaming. The rapid eye movements were absent during dream periods of three men with life-long blindness, and of two men, 30 and 40 years blind respectively, but were present during dream periods in three men blind only 3, 10 and 15 years respectively.

An LPS based method to stimulate the inflammatory response in growing rabbits

<p>Reliable indicators are needed to study the relationship between the inflammatory response of the growing rabbit and breeding factors such as feeding practices. A lipopolysaccharide (LPS) stimulation of the inflammatory response is a valid model of bacterial infection in laboratory animals, but no data on the growing rabbit has yet been obtained. The aim of our study was to determine an adequate dose of LPS to inject in growing rabbits in order to elicit a measurable inflammatory response in terms of plasmatic TNF-α and rise in rectal temperature. Three trials were carried out in this study: 2 development trials, the first (n=18) testing 3 doses of LPS (2, 10, 50 μg/kg) on the plasmatic TNF-α concentration at 90 and 180 min post injection, and the second trial (n=36) testing 4 doses of LPS (50, 75, 100 and 150 μg/kg) on the TNF-α concentration 90 min post injection and the rectal temperature. The third trial was designed as an application of the method in a large number of animals (n=32) to study the effect of feed restriction and dietary increase in digestible fibre to starch ratio on the LPS inflammatory challenge response of growing rabbits. In development trials 1 and 2, animals had measurable TNF-α responses for doses higher than 10 μg/kg at 90 min post injection, with an increase in the number of responsive animals along with the dose. High variability was observed in TNF-α concentrations in responsive animals (coefficient of variation from 44 to 94%). Animals demonstrated an increase in rectal temperature for all doses injected in the range of 50-150 μg/kg from 90 min post injection with a peak at 180 min (Δ_Tr=1.9±0.7°C). Our observations led us to choose a dose of 100 μg/kg of LPS for our following studies, as the responses in terms of temperature and TNF-α were the most satisfactory. The application of our LPS injection protocol to our nutritional study enabled us to validate our protocol (Δ_Tr=1.1±0.7°C at 180 min and 15/32 TNF-α responsive animals) even though we were not able to demonstrate any effect of the feeding level or diet on the inflammatory response to an LPS injection.</p><p> </p>

Mycotoxin co-contamination of food and feed: meta-analysis of publications describing toxicological interactions

Most fungi are able to produce several mycotoxins simultaneously; moreover food and feed can be contaminated by several fungi species at the same time. Thus, humans and animals are generally not exposed to one mycotoxin but to several toxins at the same time. Most of the studies concerning the toxicological effect of mycotoxins have been carried out taking into account only one mycotoxin. In the present review, we analysed 112 reports where laboratory or farm animals were exposed to a combination of mycotoxins, and we determined for each parameter measured the type of interaction that was observed. Most of the published papers concern interactions with aflatoxins and other mycotoxins, especially fumonisins, ochratoxin A and trichothecenes. A few papers also investigated the interaction between ochratoxin A and citrinin, or between different toxins from Fusarium species. Only experiments with a 2×2 factorial design with individual and combined effects of the mycotoxins were selected. Based on the raw published data, we classified the interactions in four different categories: synergistic, additive, less than additive or antagonistic effects. This review highlights the complexity of mycotoxins interactions which varies according to the animal species, the dose of toxins, the length of exposure, but also the parameters measured.

Influence of administration route on the biotransformation of amoxicillin in the pig

A comparison was made in the plasma concentration of the major metabolites of amoxicillin (AMO), i.e. amoxicilloic acid (AMA) and amoxicillin diketopiperazine-2',5'-dione (DIKETO) in portal and jugular venous plasma after oral (p.o.) and intravenous (i.v.) AMO administration to pigs, in order to study a possible presystemic degradation of AMO in the gastro-intestinal tract and liver. Almost identical plasma concentration-time curves were obtained for AMO and its metabolites in portal and jugular venous plasma, both after p.o. and i.v. AMO administration. Almost immediately after i.v. AMO administration, high AMA and DIKETO concentrations were measured in plasma, while after p.o. dosing, the metabolites appeared in plasma after almost complete absorption of AMO. No significant differences in pharmacokinetic parameters of AMO, AMA and DIKETO, derived from the concentration-time profiles in portal and jugular venous plasma were calculated, both after i.v. and p.o. AMO administration (P > 0.05). After p.o. administration, the half-life of elimination (t(1/2(el))) for AMA is at least two or three times the t(1/2(el)) of AMO (0.75 h for AMO vs. 2.69 h for AMA), indicating the slower clearance of the metabolite. It could be hypothesized that AMA is only eliminated by glomerular filtration, as its open beta-lactam structure might not be recognized by the transport carrier in the proximal tubule of the kidney. The results of the study indicate that AMO is not substantially metabolized presystemically in the gut and liver. Therefore, it may be assumed that the kidney may be the major organ for AMO biotransformation. Future in vivo and in vitro experiments should be performed to state this hypothesis.

Dietary glucomannan improves the vaccinal response in pigs exposed to aflatoxin B1 or T-2 toxin

The aim of the study was to investigate whether dietary supplementation with yeast-derived glucomannan protects pigs against the deleterious effects that exposure to aflatoxin B1 (AFB1) or T-2 toxin has on the vaccinal immune response and drug-metabolising enzymes. Three doses of pure mycotoxin (AFB1 trial: 482, 968 and 1,912 µg/kg feed; T-2 toxin trial: 593, 1,155 and 2,067 µg/kg feed) with or without dietary glucomannan supplementation (2 g/ kg feed) were tested in weaned pigs for 28 days. At days 4 and 15 pigs were immunised with ovalbumin to study the humoral and cell-mediated antigen-specific immune responses. The effects of AFB1 and T-2 toxin intake alone in pigs have already been published. In all parameters investigated no differences were apparent between animals receiving the unsupplemented control diet or the control diet containing glucomannan. In the AFB1 trial glucomannan decreased the severity of liver lesions in animals exposed to 968 µg/kg feed. Exposure to both AFB1 and T-2 toxin were associated with impaired phase I liver enzyme activities, but glucomannan demonstrated a limited protective effect on these enzymes. With regard to the immune defence system, both toxins modulated the vaccinal immune response; AFB1 impaired specific cellular response and T-2 toxin the specific humoral response. Glucomannan supplementation restored the ovalbumin-specific lymphocyte proliferation that was delayed in pigs exposed to AFB1, regardless of dose. In the T-2 toxin trial glucomannan supplementation restored anti-ovalbumin immunoglobulin G production, which was significantly reduced in pigs exposed to both medium and high doses of the toxin. In conclusion, glucomannan dietary supplementation demonstrated no deleterious effects in control animals and protective effects against AFB1 and T-2 toxin immunotoxicity during a vaccinal protocol.

Two isostructural triboluminescent lanthanide complexes

(4-Dimethylaminopyridine)tris(2,2,6,6-tetramethylheptane-3, 5-dionato)terbium(III), [Tb(C(11)H(19)O(2))(3)(C(7)H(10)N(2))], and its samarium analogue, [Sm(C(11)H(19)O(2))(3)(C(7)H(10)N(2))], are isostructural. Their polar space group is consistent with observed second harmonic generation and with the involvement of piezoelectric charging in their intense triboluminescence properties, which are of interest for the development of damage sensors in composite materials. The metals display irregular seven-coordination by one substituted pyridine and three chelating diketonate ligands, bond lengths to Tb being shorter than those to Sm.

Inhibitory activity of anti-interleukin-4 and anti-interleukin-10 antibodies on Toxoplasma gondii proliferation in mouse peritoneal macrophages cocultured with splenocytes from infected mice

Cocultures of splenocytes from Toxoplasma gondii-immunized mice or from naive mice, separated by a transwell membrane from naive macrophage layers, induced a decrease in T. gondii proliferation in macrophages in comparison with cultures without splenocytes or cocultures with splenocytes from infected mice. Interleukin 4 (IL-4) and IL-10 levels increased in cocultures of splenocytes from infected mice with naive macrophages. In contrast, the levels of these cytokines decreased in cocultures with splenocytes from immunized mice. No correlation was found between the release of interferon-gamma (IFN-gamma) and the inhibition of parasite multiplication. Cocultures with splenocytes from immunized mice induced an increase in tumor necrosis factor-alpha (TNF-alpha) levels. In contrast, in cocultures with splenocytes from infected mice, TNF-alpha production decreased. In cocultures with splenocytes from infected mice, T. gondii proliferation in macrophages was neutralized by anti-IL4 or anti-IL10 antibodies and was associated with increased TNF-alpha production. Moreover, this study demonstrates the significant combined effect of IL-4 and IL-10 on the down-regulation of macrophage-effector functions. A soluble positive signal was given by splenocytes to induce the production of TNF-alpha by macrophages. This signal was inhibited by IL4 and IL10. This process is biologically relevant in the regulation of T. gondii proliferation.

Vaccination routes that fail to elicit protective immunity against Schistosoma mansoni induce the production of TGF-beta, which down-regulates macrophage antiparasitic activity

C57BL/6 mice immunized intradermally (i.d.) with bacillus Calmette Guerin (BCG) plus killed skin-stage schistosomula are protected against subsequent infection with Schistosoma mansoni, whereas immunization by i.v. or i.m. routes is not protective. Moreover, previous immunization via the nonprotective i.v. route interfered with the ability to subsequently induce protection by i.d. vaccination, suggesting that inhibitory responses are invoked. Given the evidence that activated macrophages (M phi) play a role as effector cells in protection against schistosomiasis, we investigated the ability of spleen cells from protected and nonprotected immunized mice to produce M phi activating and deactivating cytokines. Exposure to supernatant fluids (SNs) from Ag stimulated spleen cells of i.d., but not i.v. or i.m., immunized mice activated inflammatory M phi for in vitro killing of schistosome larvae, through a mechanism dependent on both IFN gamma and TNF-alpha. No evidence was observed for the preferential induction of the M phi activating Th1 cytokines IFN-gamma and IL-2 in i.d. immunized mice, nor did spleen cells from nonprotected animals produce higher levels of the Th2 associated cytokines IL-4 and IL-10, which are known to prevent M phi activation. TGF-beta was, however, detected in SNs from unprotected mice. Moreover, the M phi inhibitory activity detected in these SNs was heat stable and neutralized by anti-TGF-beta Abs, suggesting that production of TGF-beta is at least partially responsible for the failure of i.m. and i.v. immunized mice to develop immunity to S. mansoni. Thus, the induction of down-regulatory cytokines may be an important factor limiting the efficacy of certain vaccination protocols.

Vaccination routes that fail to elicit protective immunity against Schistosoma mansoni induce the production of TGF-beta, which down-regulates macrophage antiparasitic activity

C57BL/6 mice immunized intradermally (i.d.) with bacillus Calmette Guerin (BCG) plus killed skin-stage schistosomula are protected against subsequent infection with Schistosoma mansoni, whereas immunization by i.v. or i.m. routes is not protective. Moreover, previous immunization via the nonprotective i.v. route interfered with the ability to subsequently induce protection by i.d. vaccination, suggesting that inhibitory responses are invoked. Given the evidence that activated macrophages (M phi) play a role as effector cells in protection against schistosomiasis, we investigated the ability of spleen cells from protected and nonprotected immunized mice to produce M phi activating and deactivating cytokines. Exposure to supernatant fluids (SNs) from Ag stimulated spleen cells of i.d., but not i.v. or i.m., immunized mice activated inflammatory M phi for in vitro killing of schistosome larvae, through a mechanism dependent on both IFN gamma and TNF-alpha. No evidence was observed for the preferential induction of the M phi activating Th1 cytokines IFN-gamma and IL-2 in i.d. immunized mice, nor did spleen cells from nonprotected animals produce higher levels of the Th2 associated cytokines IL-4 and IL-10, which are known to prevent M phi activation. TGF-beta was, however, detected in SNs from unprotected mice. Moreover, the M phi inhibitory activity detected in these SNs was heat stable and neutralized by anti-TGF-beta Abs, suggesting that production of TGF-beta is at least partially responsible for the failure of i.m. and i.v. immunized mice to develop immunity to S. mansoni. Thus, the induction of down-regulatory cytokines may be an important factor limiting the efficacy of certain vaccination protocols.

Demonstration of the target molecule of a protective IgE antibody in secretory glands of Schistosoma japonicum larvae

We have demonstrated that a mouse monoclonal IgE antibody, SJ18 epsilon.1, recognizes a 97 kDa surface molecule (Sj97) of Schistosoma japonicum larvae and that the antibody induces partial but significant protection against the skin to lung-stage of S. japonicum infection. The antibody stimulates eosinophil- and macrophage-mediated killing of schistosomula in vitro. In the present study, we isolated the putative full-length cDNA of Sj97 by screening a lambda gt11 cDNA library from S. japonicum adult worms with SJ18 epsilon.1. The predicted amino acid sequence of the cDNA showed highly significant homology to that of S. mansoni paramyosin, a potential vaccine candidate for schistosomiasis. The deletion mutants of S. japonicum paramyosin were expressed in Escherichia coli and the translation product of 443 amino acid residues of paramyosin was found to be recognized by the antibody. Moreover, we observed by immunoelectron microscopy the presence of paramyosin in the post-acetabular gland as well as in the tegument and muscle layers of the larvae. These results suggest that paramyosin is a secretory protein which may be incorporated into the tegument during the development of schistosomula, thus becoming a target for protective immunity during the migratory phase of the parasite.

Hypnotics and sleep physiology: a consensus report. European Sleep Research Society, Committee on Hypnotics and Sleep Physiology

The effects of hypnotics on descriptive and functional aspects of electrophysiological sleep parameters are assessed in this report. Because of the arbitrary definition of some of the criteria underlying the conventional sleep stage scoring procedure, computer-aided methods of EEG analysis have become increasingly important for recording and interpreting pharmacological effects on sleep. Of particular interest are the changes of EEG slow-wave activity, since this parameter varies as a function of prior sleep and waking. Several types of interaction between hypnotics and sleep regulation are discussed, some recent pharmacological developments are highlighted, and some common problems in clinical trials are specified.

Can a rapidly-eliminated hypnotic cause daytime anxiety?

To test further the conclusions of preliminary reports that regular use of a rapidly-eliminated hypnotic might cause daytime anxiety, 82 women and 38 men, mean age 53, who claimed to be poor sleepers, took a capsule nightly for 45 nights. On 25 consecutive nights the capsule contained triazolam 0.5 mg (40 subjects), lormetazepam 2 mg (40 subjects) or continued placebo (40 subjects). Both drugs improved sleep, but compared with placebo or lormetazepam-takers, triazolam-takers became more anxious on self-ratings, were judged more often to have had a bad response by an observer, more often wrote down complaints of distress, and suffered weight loss. After about 10 days of regular triazolam they tended to develop panics and depression, felt unreal, and sometimes paranoid. The very short life of triazolam, leading to daytime withdrawal symptoms, may account for some of the observations, but enhancement of benzodiazepine inverse agonist activity is also hypothesized.

Effects of repeated ritanserin on middle-aged poor sleepers

Nine subjects who believed themselves to be poor sleepers, of mean age 58 years, took a placebo for 7 days, then ritanserin 5 mg for 20 days, followed by 3 days on placebo. Sleep was recorded electrophysiologically on 2 nights during baseline, 2 early drug nights, 2 late drug nights and the 2nd and 3rd withdrawal nights. Ratings of sleep quality were collected each morning. Ritanserin, a 5HT2 antagonist, caused a persistent doubling of the amount of EEG slow wave sleep, without altering the total duration of sleep. Ritanserin decreased the frequencies of awakening and after about a week it appeared to improve the subjective quality of sleep. Sleep was then impaired during withdrawal, as indicated by decreased duration and poorer subjective quality, being worst on the 3rd withdrawal night.

The hypnotic effects of an antihistamine: promethazine

Twelve volunteer poor sleepers of mean age 59 years took placebo on one night, promethazine 20 mg on one night and promethazine 40 mg on one night, in a double-blind balanced order study. Sleep in the EEG laboratory was increased by nearly 1 h after either dose of promethazine, and sleep interruptions were reduced. Slow-wave sleep was unaffected, but the larger dose reduced the percentage of sleep spent as REM sleep. Sleep was improved subjectively by both doses of promethazine which appears to be an effective hypnotic.

No effects on sleep of a histamine H1-receptor antagonist: temelastine

Twelve volunteer poor sleepers of mean age 57 years took placebo on each of 3 consecutive nights, and temelastine 100 mg on 3 consecutive nights in a double-blind balanced order study. Sleep in the EEG laboratory was unaffected by the drug.

Effects of paroxetine on human sleep

In a first double-blind, balanced order study, 12 subjects, mean age 57 years, took placebos at bedtime on 2 nights, paroxetine 15 mg on 2 nights and paroxetine 30 mg on 2 nights. In a second study, 12 subjects, mean age 56 years, took placebos on 2 mornings and paroxetine 30 mg on 2 mornings. Electrophysiological measures of all-night sleep were made on each night subsequent to medication. Paroxetine caused more frequent awakenings, reduced total sleep and strongly suppressed REM sleep, especially the 30 mg dosage. When it had been taken in the morning, paroxetine additionally delayed sleep onset and increased slow-wave sleep.

Physiological and psychological differences between good and poor sleepers

Eighteen poor sleepers and 18 good sleepers of mean age 52 yr, selected on the basis of their stated opinions about their sleep, were studied as pairs matched for sex, age, height and weight, on five consecutive nights and two consecutive days. Using EEG measures, the poor sleepers woke more often in the early hours of sleep and achieved half an hour less sleep. They had higher body temperatures by day and night and were more anxious. They tended to have higher urinary cortisol and adrenaline excretion. The groups did not differ in reaction time nor in excretion of urinary 3-methylhistidine. The poor sleepers over-estimated their sleep latency and both groups under-estimated their total sleep, the poor sleepers being significantly more inaccurate. It is concluded that those who complain of poor sleep have also metabolic differences from good sleepers.

On serious violence during sleep-walking

It is not sufficiently realised that sleep-walking is not an hysterical condition, nor in any way related to epilepsy, nor that it can be accompanied by violent injury to the self or others. Three case reports here include that of a 14-year-old boy who rose from his bed at 2 a.m. and severely stabbed his five-year-old girl cousin. The sleeping mind is not in touch with reality and amnesia for events during sleep is usual.

Fitness facilitates sleep

Eight army recruits were studied at the start, middle, and end of their initial 18-week training programme. At each point the subjects were studied for four consecutive nights in the sleep laboratory. Their sleep was characterized by the means of the recordings on the last two nights. Within 2 days of the sleep recordings (but never on the same day) each subject spent 2 non-consecutive days in the exercise laboratory. On the 1st day a maximum oxygen consumption (VO2 max) measurement was performed on a treadmill and on the 2nd day a 24-min progressive exercise bicycle ergometer test was carried out with simultaneous venous sampling (for lactic acid measurements) and oxygen consumption recordings from which the lactate turn point (LTP) was calculated. LTP was used as a measure of fitness. Approximately 1 week after the above measures lean muscle mass as calculated by total body potassium estimation was obtained for each subject. Slow wave sleep (SWS) as a percentage of total sleep time increased significantly between the start and the measurements at 9 and 18 weeks, being 21.9%, 29.9%, and 28.5% respectively. Anaerobic threshold increased significantly (P less than 0.05) over the first 9 weeks and continued to increase to the end of the training period (P less than 0.001) using VO2 when lactate level was 2 mmol/l as a percentage of VO2 max. With increase in fitness, sleep onset latency and wake time during sleep decreased and sleep efficiency improved. The results suggest that as fitness increases sleep quality improves.